Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Pfaar, Oliver [VerfasserIn]   i
 Anders, Clemens Frithjof [VerfasserIn]   i
 Hörmann, Karl [VerfasserIn]   i
 Klimek, Ludger [VerfasserIn]   i
Titel:Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis
Titelzusatz:a randomized double-blind, placebo-controlled trial
Verf.angabe:O. Pfaar, J. Mullol, C. Anders, K. Hörmann, L. Klimek
Jahr:2012
Umfang:8 S.
Fussnoten:DOI fehlerhaft ; Gesehen am 08.08.2018
Titel Quelle:Enthalten in: Rhinology
Ort Quelle:Amsterdam : Journal Rhinology, c/o AMC, 1963
Jahr Quelle:2012
Band/Heft Quelle:50(2012), 1, Seite 37-44
ISSN Quelle:1996-8604
Abstract:Summary: Aim: To evaluate the efficacy and safety of a phytotherapeutic nasal spray containing Cyclamen europaeum (CE) in the treatment of acute rhinosinusitis (ARS). Material/Methods: We performed a randomized, double-blind, placebo-controlled trial of CE nasal spray once daily for 15 days in 99 adult patients with moderate-to-severe ARS who also received amoxicillin 500 mg three times daily for the first 8 days. The primary endpoint was the change in mean total symptom scores (TSS) on day 7. Secondary endpoints included individual symptom scores (nasal congestion, mucus secretion, facial pain, impairment of smell) and endoscopic findings on days 7 and 15 and others. Results: No statistically significant difference in TSS was noted for CE versus placebo on day 7. Moreover, the individual scores were not statistically different between the groups for the ITT-population on day 7. However, both a reduction in facial pain (PP) and an improvement in endoscopically-assessed mucosal obstruction (ITT) significantly favoured CE on day 7. The most common adverse events were nasal burning and mild epistaxis, but no severe adverse events were documented. Conclusion: In summary, this is the first randomized controlled trial on phytotherapy in patients with moderate-to-severe ARS demonstrating clinical safety and some encouraging effects of CE which merit to investigate hytotherapeutic products in further large-scale clinical trials.
DOI:doi:10.4193/Rhino10.096
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

DOI: https://doi.org/10.4193/Rhino10.096
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1578390966
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68293433   QR-Code
zum Seitenanfang